Valeo Financial Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Valeo Financial Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50	Closed	–	–	2004
2020 Q4	$0	Buy	+50	New	+$351	﹤0.01%	1666

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Valeo Financial Advisors's ALDX Position: Q1 2021 in Review

Valeo Financial Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2021, closing a stake of 50 shares.

Valeo Financial Advisors first reported a position in ALDX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2021.

Valeo Financial Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2021 after selling out during the quarter.
Valeo Financial Advisors sold 50 Aldeyra Therapeutics shares in Q1 2021.
Valeo Financial Advisors first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 1 quarter.
Valeo Financial Advisors's Aldeyra Therapeutics position peaked at $0 in Q4 2020.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2021.

Based on Valeo Financial Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.